Literature DB >> 71667

Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis.

J N Whitaker.   

Abstract

With a double-antibody radioimmunoassay performed on unconcentrated cerebrospinal fluid, eight of 14 patients in an acute phase of multiple sclerosis had levels of 3.4 to 15.4 ng per milliliter of the P1 fragment (residues 43-88) of myelin encephalitogenic protein. Encephalitogenic protein-P1 was found only in the acute phase and was present in six of seven persons in the first week of an exacerbation and absent in 29 multiple sclerosis patients who were stable or had a gradually progressive course. Six of 117 controls had detectable cerebrospinal fluid encephalitogenic protein-P1. Only in two of these, one with a recent cerebral infarction and one with diabetic nephropathy who was in coma, were the levels in the range encountered in patients in the acute phase of multiple sclerosis. Although not entirely specific for multiple sclerosis, the presence of material in the cerebrospinal fluid of multiple sclerosis patients cross-reacting with encephalitogenic protein-P1 appears to be a characteristic of acute exacerbations.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 71667     DOI: 10.1212/wnl.27.10.911

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

Review 1.  Cerebrospinal fluid markers in neurological disorders.

Authors:  A R Massaro; G Scivoletto; P Tonali
Journal:  Ital J Neurol Sci       Date:  1990-12

2.  Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope.

Authors:  Cheryl A D'Souza; Mario A Moscarello
Journal:  Neurochem Res       Date:  2006-07-27       Impact factor: 3.996

3.  Dual response of lymphocytes from multiple sclerosis patients to myelin basic protein.

Authors:  V Wicher; W Olszewski; F Milgrom
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

4.  The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.

Authors:  K J Lamers; B M Uitdehaag; O R Hommes; W Doesburg; R A Wevers; W J von Geel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

5.  Anti-CNS antibodies in neurological and psychiatric disorders.

Authors:  A V Plioplys; J Thibault; J P Bouchard; C Cockburn; R Hawkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-11       Impact factor: 10.154

6.  Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome.

Authors:  R Crols; J Saerens; M Noppe; A Lowenthal
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

Review 7.  Proteinases in inflammatory demyelinating disease.

Authors:  C T Bever; J N Whitaker
Journal:  Springer Semin Immunopathol       Date:  1985

8.  Myelin basic protein in cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases.

Authors:  A Biber; D Englert; D Dommasch; K Hempel
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

9.  Modifications of the cerebrospinal fluid IgG concentrations in patients with multiple sclerosis treated with intrathecal steroids.

Authors:  A R Massaro
Journal:  J Neurol       Date:  1978-12-22       Impact factor: 4.849

10.  Differences in interaction between immune complexes and complement receptors in serum and cerebrospinal fluid.

Authors:  M E Medof; J P Antel; J J Oger; G M Prince; B G Arnason
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.